Phenol Prodrugs
Disclosed herein are phenol prodrugs and pharmaceutical compositions thereof. The prodrugs and pharmaceutical compositions thereof may be used to treat or prevent medical disorders such as, for example, cystic fibrosis, cancer, COPD, asthma and many other diseases.
1 . A compound of structural formula (I) or pharmaceutically acceptable salts, solvate or hydrates thereof:
where R 1 is substituted aryl, substituted heteroaryl,
R 2 and R 4 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloheteroalkyl, substituted cycloheteroalkyl, cycloheteroalkenyl, substituted cycloheteroalkenyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl, substituted heteroarylalkenyl; R 3 is —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloheteroalkyl, substituted cycloheteroalkyl, cycloheteroalkenyl, substituted cycloheteroalkenyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl, substituted heteroarylalkenyl; R 16 and R 17 are independently alkyl or substituted alkyl; R 18 is cycloheteroalkyl fused with aryl or substituted aryl, substituted cycloheteroalkyl fused with aryl or substituted aryl or
R 21 is —H, —F, or —CF 3 ; and Y is —NH or —O—.
2 . The compound of claim 1 , wherein R 1 is NH
3 . The compound of claims 1 or 2 , wherein R 2 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl or substituted heteroarylalkenyl.
4 . The compound of claim 1 , wherein R 2 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl.
5 . The compound of claim 1 , wherein R 2 is —CH 2 CH 2 X; X is —R 5 , —OR 6 , —SR 7 , —NR 8 R 9 , —NC(O)R 10 , —NC(O)NR 11 R 12 or —NC(NR 13 )NR 14 R 15 ; R 5 —R 7 , R 10 and R 13 are alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl or substituted heteroarylalkenyl; R 8 and R 9 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl or substituted heteroarylalkenyl; R 11 and R 12 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl or substituted heteroarylalkenyl; and R 14 and R 15 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl or substituted heteroarylalkenyl.
6 . The compound of claim 5 , wherein R 5 —R 7 , R 10 and R 13 are alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl; R 8 and R 9 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl; R 11 and R 12 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl; and R 14 and R 15 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl.
7 . The compound of claim 5 , wherein X is R 5 , —OR 6 , or —NR 8 R 9 .
8 . The compound of claim 7 , wherein R 5 and R 6 are alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl; and R 8 and R 9 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl.
9 . The compound of claim 1 , wherein R 3 is —H, alkyl, substituted alkyl, cycloheteroalkyl, arylalkyl, heteroalkyl, heteroarylalkyl or substituted heteroarylalkyl.
10 . The compound of claim 1 , wherein R 4 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl or substituted heteroarylalkenyl.
11 . The compound of claim 1 , wherein R 4 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl.
12 . The compound of claim 1 of structural formula (II):
wherein X is —C(O)OR 10 , —OR 12 , or —NR 13 R 14 ; R 10 and R 11 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl or substituted heteroarylalkenyl; and R 13 and R 14 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl or substituted heteroarylalkenyl; and R 19 and R 20 are independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroarylalkyl, substituted heteroarylalkyl, heteroarylalkenyl or substituted heteroarylalkenyl.
13 . The compound of claim 12 , wherein R 10 and R 12 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl; R 13 and R 14 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl or substituted heteroalkenyl; and R 19 and R 20 are independently —H, alkyl, alkenyl, arylalkyl, substituted arylalkyl, arylalkenyl, heteroalkyl, heteroalkenyl, heteroarylalkyl or heteroarylalkenyl.
14 . The compound of claim 1 , having the structure:
15 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable vehicle.
16 . A method treating or preventing cystic fibrosis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of anyone of claim 1 .
17 . A method treating or preventing cystic fibrosis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 15 .
18 . The compound of claim 1 and a compound selected from group consisting of deuticaftor, ivacaftor, lumacaftor, tezacaftor, vanzacaftor, elexacaftor and combinations thereof.
19 . A pharmaceutical composition comprising the compound of claim 18 and a pharmaceutically acceptable vehicle.
20 . A method treating or preventing cystic fibrosis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 18 .